Literature DB >> 28635413

The high responder: a review of pathophysiology and outcomes during IVF treatment.

Mariano Mascarenhas1, Adam H Balen1.   

Abstract

This review attempts to summarize the known literature on high responders to ovarian stimulation during assisted reproductive techniques (ART). Response to gonadotrophins is subject to significant interindividual and intercycle variation, thus carrying a risk of high response or poor response to ovarian stimulation regimens. The main risk for high responders is the development of ovarian hyperstimulation syndrome (OHSS) which is associated with significant morbidity. Hence, the definition of high responders in the literature has primarily focussed on risk factors for OHSS. Strategies to reduce OHSS including tailoring of the ovarian stimulation regimens and adjusting gonadotrophin doses according to patient characteristics and findings during the cycle of stimulation. In addition, modifying the type of ovulation trigger used and adjuvant therapies, such as metformin, intravenous colloids and vascular endothelial growth factor blockers, have also been studied as options to reduce OHSS. Apart from the risk of OHSS, high response also appears to have an adverse impact on the oocyte and endometrium, though there is a paucity of data regarding the extent and mechanisms behind this impact.

Entities:  

Keywords:  IVF; OHSS; high responder; management; risk factors

Mesh:

Substances:

Year:  2017        PMID: 28635413     DOI: 10.1080/14647273.2017.1293851

Source DB:  PubMed          Journal:  Hum Fertil (Camb)        ISSN: 1464-7273            Impact factor:   2.767


  7 in total

1.  An artificial neural network for the prediction of assisted reproduction outcome.

Authors:  Paraskevi Vogiatzi; Abraham Pouliakis; Charalampos Siristatidis
Journal:  J Assist Reprod Genet       Date:  2019-06-19       Impact factor: 3.412

2.  Terminal differentiation of human granulosa cells as luteinization is reversed by activin-A through silencing of Jnk pathway.

Authors:  Gamze Bildik; Nazli Akin; Yashar Esmaeilian; Francesko Hela; Ceren Sultan Yildiz; Ece Iltumur; Said İncir; Sercin Karahuseyinoglu; Kayhan Yakin; Ozgur Oktem
Journal:  Cell Death Discov       Date:  2020-09-23

3.  Response: Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.

Authors:  Daniele Santi; Livio Casarini; Carlo Alviggi; Manuela Simoni
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-23       Impact factor: 5.555

4.  Factors predicting clinical pregnancy rate of in vitro fertilization-embryo transfer (a STROBE-compliant article).

Authors:  Yi-Le Zhang; Fu-Zhen Wang; Kai Huang; Lin-Li Hu; Zhi-Qin Bu; Jing Sun; Ying-Chun Su; Yi-Hong Guo
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

5.  Is early-follicular long-acting GnRH agonist protocol an alternative for patients with polycystic ovary syndrome undergoing in vitro fertilization?

Authors:  Di Wang; Ting Chu; Ting Yu; Jun Zhai
Journal:  Reprod Biol Endocrinol       Date:  2022-09-10       Impact factor: 4.982

Review 6.  Untapped Reserves: Controlling Primordial Follicle Growth Activation.

Authors:  Amanda Kallen; Alex J Polotsky; Joshua Johnson
Journal:  Trends Mol Med       Date:  2018-02-13       Impact factor: 11.951

7.  Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial.

Authors:  Jared C Robins; Andrew F Khair; Eric A Widra; Michael M Alper; Winnie W Nelson; Eric D Foster; Anshul Sinha; Masakazu Ando; Patrick W Heiser; Gaurang S Daftary
Journal:  F S Rep       Date:  2020-11-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.